Efficacy and Safety of the Combination Therapy Based on Eravacycline in Immunocompromised Hosts With MDROS Infection

NCT06223100 | Unknown FDA Drug

• 1 other identifier: LPan20230578
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to explore the treatment mode and clinical outcome of patients with immunocompromised who received the combined regimen of eraracycline in the treatment of multidrug-resistant bacterial infections, to evaluate the efficacy and safety of the combined regimen of eravacycline in the treatment of multidrug-resistant bacterial infections in immunocompromised host populations, and to provide data reference for the treatment of immunocompromised populations.

Conditions

Immune Dysregulation Disorder

Outcome Measures

Primary Outcomes (3)

• 30-day all-cause mortality

  Evaluate the 30-day all-cause mortality of multi-drug resistant bacterial infections in immunocompromised host populations treated with the combined regimen of eravacycline.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Clinical cure rate

  Evaluate the clinical cure rate of eravacycline treatment.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Symptom improvement rate

  Evaluate the symptom improvement rate of eravacycline treatment.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

Secondary Outcomes (6)

• Safety and tolerance of eravacycline

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Microbial clearance rate

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Impact of different treatment timing on eravacycline outcomes as assessed by 30-day all-cause mortality.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Impact of different treatment timing on eravacycline outcomes as assessed by clinical cure rates.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

• Impact of different treatment timing on eravacycline outcomes as assessed by clinical improvement rates.

  during the treatment (1-14 days); the end of treatment（Day 14）; 28-35 days after first dose

Interventions

Eravacycline DRUG

There is no other intervention.

Also known as: XERAVA

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

People with low immune function are at high risk of multidrug-resistant bacterial infections, especially those who need long-term immunosuppressive therapy, such as patients with hematological malignancies, solid organ transplant recipients, etc.

You may qualify if:

• ≥ 18 years old.
• Voluntary to participate in this study and signed informed consent. If the subject is unable to read and / or sign the informed consent due to incapacity or other reasons, the guardian of the subject is required to act as the agent of the informed process and sign the informed consent.
• In a state of low immune function:
• In this study, if the patient meets any of the following criteria, the patient 's immune function is considered to be low : 1 patients who have previously received solid organ transplantation ( liver, kidney, lung, heart ) ; 2 hematological malignancies ( leukemia, lymphoma ) ; 3 Patients received long-term immunosuppressive therapy, or used steroids that reached immunosuppressive doses within 21 months before screening ( ≥ 10 mg prednisone or \> 15 mg / kg / d hydrocortisone or d \> 3 mg / kg / d methylprednisolone, continuous d \> 5 days ) \[ 4,13 \]. 4 Severe infections occurred recently, leading to extremely low immune function.
• Infections caused by known or highly suspected multidrug-resistant pathogens (MDR), or gram-negative bacteria that are sensitive to eravacycline in adult patients with limited treatment options. The high-risk factors and standards of MDR met the definition of " Chinese expert consensus on prevention and control of nosocomial infection of multidrug-resistant bacteria "; multidrug-resistant bacteria (MDR) refer to bacteria that are resistant to three or more types of commonly used antibiotics that are usually sensitive. Multidrug resistance also includes pan-drug resistance (XDR) and pan-drug resistance (PDR).
• Patients treated with elastin ≥ 3 days.

You may not qualify if:

• Urinary tract infection.
• Clear culture results showed that microbial pathogens were not sensitive to test drugs (such as Pseudomonas aeruginosa, etc.).
• Patients whose expected survival time cannot exceed the study period.
• The researchers believe that there is any medical history, current condition, treatment, abnormal laboratory examination or other conditions that may affect the test results, interrupt the test process (or the subject cannot complete all the operations and visits required by the test) or accept the test drugs that will increase the risk of the subject. Patients with end-stage diseases have immediate life-threatening disease evidence.
• Patients with a history of allergic reactions to tetracyclines or any adjuvant contained in the study drug formula.
• Vulnerable groups other than critically ill patients, including people with mental illness, cognitive impairment, pregnant women, etc.

Sponsors & Collaborators

• Sichuan Provincial People's Hospital: lead

Biospecimen

Retention: SAMPLES WITHOUT DNA

Abdominal drainage fluid samples, blood samples, respiratory tract samples

MeSH Terms

Interventions

eravacycline

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Associate Clinical Professor

Study Record Dates

• First Submitted: January 2, 2024
• First Posted: January 25, 2024
• Study Start: February 1, 2024
• Primary Completion: December 31, 2025
• Study Completion: December 31, 2025
• Last Updated: January 25, 2024

Record last verified: 2024-01